<?xml version='1.0' encoding='utf-8'?>
<document id="23094794"><sentence text="Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers."><entity charOffset="38-51" id="DDI-PubMed.23094794.s1.e0" text="empagliflozin" /></sentence><sentence text="To investigate potential drug-drug interactions between empagliflozin and warfarin"><entity charOffset="56-69" id="DDI-PubMed.23094794.s2.e0" text="empagliflozin" /><entity charOffset="74-82" id="DDI-PubMed.23094794.s2.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.23094794.s2.e0" e2="DDI-PubMed.23094794.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23094794.s2.e0" e2="DDI-PubMed.23094794.s2.e1" /></sentence><sentence text="" /><sentence text="Healthy subjects (n = 18) received empagliflozin 25 mg qd for 5 days (treatment A), followed by empagliflozin 25 mg qd for 7 days (days 6-12) with a single 25 mg dose of warfarin on day 6 (treatment B), and a single 25 mg dose of warfarin alone (treatment C), in an open-label, crossover study" /><sentence text=" Subjects received treatments in sequence AB_C or C_AB with a washout period of ≥14 days between AB and C or C and AB" /><sentence text="" /><sentence text="Warfarin had no effect on empagliflozin area under concentration-time curve or maximum plasma concentration at steady-state (AUC(τ,ss) or C(max,ss)): geometric mean ratios (GMRs) (90% confidence intervals [CI]) were 100"><entity charOffset="26-39" id="DDI-PubMed.23094794.s7.e0" text="empagliflozin" /></sentence><sentence text="89% (96" /><sentence text="86, 105" /><sentence text="10) and 100" /><sentence text="64% (89" /><sentence text="79, 112" /><sentence text="80), respectively" /><sentence text=" Empagliflozin had no effect on AUC from 0 h to infinity (AUC(0-∞)) or C(max) for R- or S-warfarin (GMRs [90% CI] for AUC(0-∞): 98"><entity charOffset="1-14" id="DDI-PubMed.23094794.s14.e0" text="Empagliflozin" /></sentence><sentence text="49% [95" /><sentence text="29, 101" /><sentence text="80] and 95" /><sentence text="88% [93" /><sentence text="40, 98" /><sentence text="43], respectively; C(max): 97" /><sentence text="89% [91" /><sentence text="12, 105" /><sentence text="15] and 98" /><sentence text="88% [91" /><sentence text="84, 106" /><sentence text="47], respectively)" /><sentence text=" Empagliflozin had no clinically relevant effects on warfarin's anticoagulant activity (international normalised ratio [INR]) (GMR [95% CI] for peak INR: 0"><entity charOffset="1-14" id="DDI-PubMed.23094794.s27.e0" text="Empagliflozin" /></sentence><sentence text="87 [0" /><sentence text="73, 1" /><sentence text="04]; area under the effect-time curve from 0 to 168 h: 0" /><sentence text="88 [0" /><sentence text="79, 0" /><sentence text="98]" /><sentence text=" No drug-related adverse events were reported for empagliflozin after monotherapy or combined administration"><entity charOffset="50-63" id="DDI-PubMed.23094794.s34.e0" text="empagliflozin" /></sentence><sentence text=" The combination of empagliflozin and warfarin was well tolerated"><entity charOffset="20-33" id="DDI-PubMed.23094794.s35.e0" text="empagliflozin" /><entity charOffset="38-46" id="DDI-PubMed.23094794.s35.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.23094794.s35.e0" e2="DDI-PubMed.23094794.s35.e0" /><pair ddi="false" e1="DDI-PubMed.23094794.s35.e0" e2="DDI-PubMed.23094794.s35.e1" /></sentence><sentence text="" /><sentence text="No drug-drug interactions were observed between empagliflozin and warfarin, indicating that empagliflozin and warfarin can be co-administered without dosage adjustments of either drug"><entity charOffset="48-61" id="DDI-PubMed.23094794.s37.e0" text="empagliflozin" /><entity charOffset="92-105" id="DDI-PubMed.23094794.s37.e1" text="empagliflozin" /><entity charOffset="110-118" id="DDI-PubMed.23094794.s37.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.23094794.s37.e0" e2="DDI-PubMed.23094794.s37.e0" /><pair ddi="false" e1="DDI-PubMed.23094794.s37.e0" e2="DDI-PubMed.23094794.s37.e1" /><pair ddi="false" e1="DDI-PubMed.23094794.s37.e0" e2="DDI-PubMed.23094794.s37.e2" /><pair ddi="false" e1="DDI-PubMed.23094794.s37.e1" e2="DDI-PubMed.23094794.s37.e1" /><pair ddi="false" e1="DDI-PubMed.23094794.s37.e1" e2="DDI-PubMed.23094794.s37.e2" /></sentence><sentence text="" /></document>